[ad_1]
In the last quarter published, the company missed earnings forecasts of 107.1%. The company went public in July 2018.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Pipeline Progress in Focus"data-reactid =" 13 ">Pipeline Progress in Focus
Tilray produces medical cannabis in Canada and Europe. The company offers two categories of products: dried cannabis, which includes whole flowers and crushed flowers, and cannabis extracts, which include drops and full spectrum and purified oil capsules.
The company recorded a 110% improvement in revenues in 2018. This increase is due to block sales, the inaugural sales of the Canadian adult market and the acceleration of wholesale distribution in the Canadian markets. ;export. We expect this momentum to continue into the first quarter.
There is a global paradigm shift in cannabis. Medical cannabis is now authorized nationally or federally in 29 countries. Although the legal market for medical cannabis is still in its infancy, it represents a huge potential.
Recreational cannabis was legalized on October 17, 2018. This, in turn, should stimulate demand for the company's products in the first quarter. The company expects the adult consumer market to represent a larger proportion of its legalization revenues as new consumers participate and previously illicit consumers adopt the Canadian framework for sale. cannabis.
Tilray has worked to expand its global footprint. The company expanded its alliance with Sandoz, a division of Novartis NVS, in 2018 to make medical cannabis products more accessible to needy patients around the world. The company announced a research and development partnership with AB InBev. The agreement covers THC and CBD soft drinks. These partnerships will generate additional revenue in the first quarter.
In February 2019, Tilray acquired FHF Holdings Ltd. (Manitoba Harvest) with Compass Group Diversified Holdings. Manitoba Harvest is the world's largest manufacturer of hemp foods and a leader in the health food industry.
We expect investors to focus on the company's business updates when calling the first quarter results, aside from the normal numbers for the up and down.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Whispers Earnings"data-reactid =" 21 ">Whispers Earnings
Our proven model does not conclusively show that Tilray is beating its earnings this quarter. Indeed, an action must have both a positive profit PSE and a rank of Zacks of rank 1 (strong buy), 2 (buy) or 3 (pending) to be able to beat the estimates. Unfortunately, this is not the case here, as you will see below.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "ESP benefits: The CSR of the company's profits, which represents the difference between the most accurate estimate and the consensus estimate of Zacks, is + 6.75%. Indeed, the most accurate estimate lies at – $ 0.24 and the consensus estimate Zacks at – $ 0.25. You can discover the best shares to buy or sell, before they are declared, with our earnings ESP filter. "Data-reactid =" 23 ">ESP benefits: The CSR of the company's profits, which represents the difference between the most accurate estimate and the consensus estimate of Zacks, is + 6.75%. Indeed, the most accurate estimate lies at – $ 0.24 and the consensus estimate Zacks at – $ 0.25. You can discover the best shares to buy or sell, before they are declared, with our earnings ESP filter.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Zacks Rank: Tilray is currently ranked Zacks at rank 4 (sale). Please note that we are announcing conclusive results against Tier 4 or 5 (Strong Sell) Zacks stock, especially when the company sees revisions of negative estimates. "Data-reactid =" 24 ">Zacks Rank: Tilray is currently ranked Zacks at rank 4 (sale). Note that we warn against stocks with a ranking of Zacks of rank 4 or 5 (strong selling) in the announcement of the results, especially when the company sees negative estimates revisions.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Share price performance"data-reactid =" 25 ">Share price performance
Tilray's stock has lost 31.9% in the year so far, compared to an industry growth of 8.8%.
<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Stocks to consider"data-reactid =" 36 ">Stocks to consider
Here are some titles of health products that you may want to consider, as our model shows that they have the right mix of items to generate better results this quarter.
[ad_2]
Source link